Head of Regeneron Cell Medicines

Head of Regeneron Cell Medicines

Location:

Cambridge, MA (primary site)

The Head of Regeneron Cell Medicines (RCM) sets the vision, strategy, and execution for Regeneron’s cell medicines portfolio and technology platform. Scope includes ex vivo and in vivo CAR T programs and enabling technologies for delivery, including chemo‑free conditioning. This leader oversees cross‑functional initiatives from discovery through early clinical development, builds and mentors high‑performing teams, and partners across the enterprise and with external collaborators to deliver transformative cell‑based therapies.

Based in Cambridge, MA, this role serves as the site’s senior scientific executive and advances the RCM portfolio in alignment with Regeneron’s broader scientific vision.

• Define and drive the long‑term scientific vision and portfolio strategy for ex vivo and in vivo cell medicines, aligned to enterprise priorities.
• Prioritize programs and platform investments using data‑driven governance, scenario planning, and risk/benefit frameworks.
• Champion innovation in cell engineering, in vivo delivery (e.g., LNPs, viral vectors), and manufacturing to create differentiated therapies.
• Establish and evolve the CAR T strategy, including target selection, tissue/cell targeting, potency enhancement, and combinations with antibody‑based approaches.

• Lead matrixed teams to deliver milestones from target validation to IND, Phase I manufacturing, and early clinical readouts.
• Guide technical problem solving across modalities, including CAR T design, delivery optimization, biodistribution/PK, on/off‑target assessment, and safety risk mitigation.
• Integrate enabling platforms where justified (e.g., CAR Ts, antibody‑based approaches such as CPIs and bispecifics, encoded potency enhancements, ARMoR’ing strategies).
• Drive benign conditioning initiatives that enable chemo‑free delivery of cell‑based medicines (including T cells and hematopoietic stem cells).

• Build, mentor, and retain a diverse, high‑performing organization of senior scientific leaders and functional experts.
• Foster a culture of scientific excellence, accountability, collaboration, and inclusion across sites and functions.
• Implement succession planning, talent development, and performance management.

• Partner closely with Research, Preclinical Development, Clinical, Regulatory, Quality, CMC, Manufacturing, BD, and Finance.
• Serve as the senior scientific leader for the Cambridge site; maintain strong operating rhythms with Seattle and Tarrytown leadership.
• Coordinate with vector/delivery, immunology, and translational biomarker teams to accelerate RCM programs to clinical evaluation.

• Identify and evaluate external opportunities (academia, biotech, consortia, platforms) to accelerate the pipeline and capabilities.
• Negotiate and govern collaborations to clear, value‑creating outcomes.

• Own budgets, headcount planning, and resource allocation across programs and platform functions.
• Ensure adherence to biosafety, ethical guidelines, and regulatory standards (e.g., IND enabling, GxP interfaces), including nonclinical programs specific to ex vivo and in vivo cell therapy (biodistribution, preclinical safety).
• Drive reproducibility, data integrity, and robust decision records.

• Provide clear, concise updates to executive leadership and governance bodies on strategy, progress, risks, and mitigation plans.
• Represent Regeneron Cell Medicines at internal and external forums, scientific conferences, and with partners.

• Advanced degree (PhD, MD, or MD/PhD) in cell biology, immunology, bioengineering, or related discipline.
• 20+ years of biopharmaceutical R&D experience with a substantial focus on cell‑based therapies; track record advancing programs from discovery to IND and early clinical.
• Demonstrated leadership of multidisciplinary, multisite teams and senior people…